Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Human ACMSD-1 Inhibitor Assay from US Patent US11780812: "Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors"
Assay data:55 Active, 45 Activity ≤ 1 µM, 57 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Spectrophotometrical In Vitro Assay from US Patent US11254644: "Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase"
Assay data:22 Active, 18 Activity ≤ 1 µM, 22 Tested
spectrophotometrical in vitro assay from US Patent US10513499: "Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase"
ACMSD1 Inhibition Assay from US Patent US9708272: "Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase"
Inhibition of human ACMSD in presence of 10 uM 3-HAA by coupled assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human ACMSD using ACMS substrate by spectrometry
Assay data:7 Active, 1 Activity ≤ 1 µM, 16 Tested
Competitive inhibition of human ACMSD using ACMS substrate by spectrometry
Assay data:1 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of ACMSD (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)
Assay data:26 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)
Inhibition of human recombinant ACMSD1 expressed in Escherichia coli BL21 (DE3) cells assessed as reduction in conversion of 3-OH-anthranilic acid into ACMS by spectrophotometry
Assay data:10 Active, 15 Activity ≤ 1 µM, 15 Tested
Inhibition of ACMSD in in human Hepa1-6 cells assessed as increase in Sod2 mRNA expression incubated for 24 hrs by RT-qPCR analysis
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD\\"\\" concentration following compound replacement every 24 hrs by LC-MS/MS analysis relative to control
Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 250 uM following compound replacement every 24 hrs by LC-MS/MS analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 500 uM following compound replacement every 24 hrs by LC-MS/MS analysis relative to control
Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 5 uM following compound replacement every 24 hrs by LC-MS/MS analysis
Inhibition of ACMSD in human primary hepatocytes assessed as increase in NAD concentration at 0.5 uM following compound replacement every 24 hrs by LC-MS/MS analysis
Assay data:2 Active, 2 Tested
Inhibition of human recombinant ACMSD1 expressed in HEK293T cells assessed as reduction in conversion of 3-OH-anthranilic acid into ACMS by spectrophotometry
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on